NextPlat Corp. (NASDAQ:NXPL) Sees Significant Decrease in Short Interest

NextPlat Corp. (NASDAQ:NXPL) was the target of a significant decrease in short interest in June. As of June 15th, there was short interest totaling 11,956 shares, a decrease of 63.8% from the May 31st total of 33,021 shares. Approximately 0.8% of the company’s stock are short sold. Based on an average trading volume of 31,212 shares, the short-interest ratio is currently 0.4 days.

Key NextPlat News

Here are the key news stories impacting NextPlat this week:

• Positive Sentiment: Litchfield Hills Research initiated coverage on NextPlat with a Buy rating and a $11.00 price target, suggesting substantial upside potential. Street Insider article
• Positive Sentiment: The analyst sees NextPlat moving toward profitability, forecasting FY2027 EPS of $0.57 and positive quarterly EPS in 2027, which may improve longer-term sentiment. Benzinga article
• Neutral Sentiment: New earnings estimates for FY2026 (-$0.55 EPS) and Q2 2026 (-$0.21 EPS) still indicate losses in the near term, limiting immediate upside. Tickerreport article
• Neutral Sentiment: Short interest data showed a decline earlier in the month, but the most recent update reported 0 shares short, making the data unusual and hard to interpret for trading impact. American Banking News article
• Negative Sentiment: The latest analyst estimates still call for losses through most of 2026, including Q3 2026 EPS of $0.00 and Q4 2026 EPS of $0.07, so investors may remain cautious about near-term earnings power. Benzinga article

Hedge Funds Weigh In On NextPlat

A hedge fund recently bought a new position in NextPlat stock. Citadel Advisors LLC bought a new stake in NextPlat Corp. (NASDAQ:NXPL) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 48,176 shares of the company’s stock, valued at approximately $40,000. Citadel Advisors LLC owned about 0.19% of NextPlat at the end of the most recent reporting period. 1.30% of the stock is owned by institutional investors and hedge funds.

NextPlat Price Performance

NXPL stock opened at $6.15 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.12 and a current ratio of 2.56. The business has a 50-day simple moving average of $6.39 and a two-hundred day simple moving average of $5.93. The company has a market capitalization of $16.67 million, a P/E ratio of -1.42 and a beta of 1.90. NextPlat has a 52-week low of $3.38 and a 52-week high of $11.10.

NextPlat (NASDAQ:NXPL) last posted its earnings results on Thursday, May 14th. The company reported ($0.42) earnings per share for the quarter. NextPlat had a negative net margin of 23.14% and a negative return on equity of 58.05%. The company had revenue of $9.86 million during the quarter. Research analysts expect that NextPlat will post -0.55 EPS for the current fiscal year.

Wall Street Analyst Weigh In

NXPL has been the subject of several recent research reports. Zacks Research upgraded NextPlat to a “hold” rating in a report on Thursday. Litchfield Hills Research began coverage on shares of NextPlat in a research report on Wednesday. They issued a “buy” rating and a $11.00 price target for the company. Finally, Weiss Ratings upgraded shares of NextPlat from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, NextPlat presently has a consensus rating of “Hold” and a consensus price target of $11.00.

NextPlat Company Profile

NextPlat Corp operates as a healthcare and e-commerce company in Europe, North America, South America, the Asia and Pacific, and Africa. The company operates full-service retail specialty services pharmacies that provides prescription pharmaceuticals prescription pharmaceuticals, third-party administration, risk and data management services, compounded medications, tele-pharmacy services, anti-retroviral medications, medication therapy management, contracted pharmacy services, and health practice risk management to healthcare organizations and providers, as well as supplies prescription medications to long-term care facilities.